Chemical compound
Pharmaceutical compound
Kappadione |
|
Routes of administration | Injection |
---|
ATC code | |
---|
|
Legal status |
- US: Rx only, discontinued (was FDA approved)
- In general: ℞ (Prescription only)
|
---|
|
Tetrasodium (2-methyl-4-phosphonatooxynaphthalen-1-yl) phosphate
|
CAS Number | |
---|
PubChem CID | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
KEGG | |
---|
CompTox Dashboard (EPA) | |
---|
ECHA InfoCard | 100.004.558 |
---|
|
Formula | C11H8Na4O8P2 |
---|
Molar mass | 422.084 g·mol−1 |
---|
3D model (JSmol) | |
---|
CC1=C(C2=CC=CC=C2C(=C1)OP(=O)([O-])[O-])OP(=O)([O-])[O-].[Na+].[Na+].[Na+].[Na+]
|
InChI=1S/C11H12O8P2.4Na/c1-7-6-10(18-20(12,13)14)8-4-2-3-5-9(8)11(7)19-21(15,16)17;;;;/h2-6H,1H3,(H2,12,13,14)(H2,15,16,17);;;;/q;4*+1/p-4 NKey:GZBACHSOZNEZOG-UHFFFAOYSA-J N
|
NY (what is this?) (verify) |
Kappadione is a vitamin K derivative used for the treatment of side effects of vitamin K antagonists such as warfarin, prophylaxis and treatment of vitamin K deficiency bleeding, and hypoprothrombinemia due to various causes.[1] It was manufactured by Eli Lilly and Company.[2] Chemically, it is menadiol sodium diphosphate. It was approved by the US Food and Drug Administration prior to 1982 and marketed by Lilly. It has since been discontinued and is not available in North America.[1]
References